Date: 2012-10-15
Type of information: Production agreement
Compound: Lymfactin®
Company: Ark Therapeutics (UK) Laurantis Pharma (Finland)
Therapeutic area: Cancer - Oncology
Type agreement: manufacturing
production
Action mechanism:
Disease: breast cancer-associated lymphedema
Details: Ark Therapeutics has been selected to manufacture and supply Lymfactin® to Laurantis Pharma under a conditional agreement announced by the Finland-based companies. The agreement is subject to Laurantis receiving regulatory approval to commence its phase I clinical trial. Specific terms of the agreement are not disclosed. Lymfactin® uses an adenoviral vector to deliver vascular endothelial growth factor (VEGF-C) during transplantation of lymph nodes in order to avoid lymphedema.
The phase I clinical trial using Lymfactin® to treat breast cancer-associated lymphedema is targeted to begin in 2013, and will recruit patients in the USA and Finland. Breast cancer-associated lymphedema is the most common form of secondary lymphedema, occurring in approximately 20% of breast cancer patients who undergo axillary lymph node dissection. The incidence is even higher in those who also receive radiotherapy, and this complication may even occur in those who undergo a lymph node biopsy as part of treatment. No therapeutic treatment currently exists to treat this disease.
Financial terms:
Latest news:
